Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-22
2005-11-22
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S323000, C514S336000, C514S337000, C514S903000
Reexamination Certificate
active
06967210
ABSTRACT:
N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
REFERENCES:
patent: 4880822 (1989-11-01), Effland et al.
patent: 4970218 (1990-11-01), Effland et al.
patent: 43 25 491 (1995-02-01), None
patent: 0287982 (1988-10-01), None
patent: 0415103 (1991-03-01), None
patent: 0683165 (1995-11-01), None
patent: 0731108 (1996-09-01), None
patent: WO96/14066 (1996-05-01), None
patent: WO01/04091 (2001-01-01), None
C.T. Bever, Jr., The Current Status of Studies of Aminopyrides in Patients with Multiple Sclerosis, Annals of Neurology, Boston, MA, vol. 36, 1994, pp. S118-S121.
L. Tang et al., 4-Aminopyridine Derivatives: A Family of Novel Modulators of Voltage-Dependent Sodium Channels, Drug Development Research, vol. 44, No. 1, May 1998, pp. 8-13.
L. Tang et al., Effects of besipirdine at the voltage-dependent sodium channel, British Journal of Pharmacology, vol. 116, No. 5, 1995, pp. 2468-2472.
M Abou-Gharbia et al., IV Congress of the ECNP, Aggression and anxiety are the first components to respond to antidepressant therapy, Drug News and Perspectives, vol. 4, No. 10, Dec. 1, 1991, pp. 647-650.
P. Villoslada et al., Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System, Journ. of Experimental Medicine, vol. 191, No. 10, May 15, 2000, pp. 1799-1806.
R.M. Eglen et al., Muscarinc receptor ligands and their therapeutic potential, Current Opinion in Chemical Biology, vol. 3, No. 4, Aug. 1999, pp. 426-432.
W.J. Mysiw et al., Medications To Enhance Cognitive Functioning, Physical Medicine and Rehabilitation Clinics of North America, 1997, pp. 781-800.
Petty Margaret
Rampe David
Rathbone Michel P.
Smith Craig P.
Aventis Pharmaceuticals Inc.
Jones Dwayne
Kurys Barbara E.
LandOfFree
Method of treating of demyelinating diseases or conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating of demyelinating diseases or conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating of demyelinating diseases or conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3485396